Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate

Vaccine. 1995 Aug;13(12):1080-5. doi: 10.1016/0264-410x(95)00048-6.


Successful vaccination against the human cytomegalovirus (HCMV) requires induction of both neutralizing antibody and cytotoxic T lymphocyte (CTL) responses. The HCMV glycoprotein B (gB, UL55) would be one of the most important immunogens to induce neutralizing antibodies. We tested the immunogenicity of an ALVAC (canarypox)-HCMV-gB (ALVAC-gB) recombinant in mice and guinea pigs in order to provide preclinical data for a phase I clinical trial of a HCMV vaccine candidate. ALVAC is an attenuated vaccine strain of canarypox virus which replicates productively in avian species but abortively in mammalian cells. The ALVAC-gB recombinant inoculated subcutaneously in mice and intramuscularly in guinea pigs induced HCMV-specific neutralizing antibodies and gB-specific CTL responses. Ultraviolet irradiation of the ALVAC-gB recombinant before immunization diminished CTL responses, indicating that intracellular expression and processing of gB-protein were necessary for CTL induction. Prior immunity to vaccinia virus did not decrease immunogenicity of the ALVAC-gB recombinant in mice. Thus, despite its host range restriction, ALVAC-gB is potentially capable of inducing both humoral and cell-mediated immune responses to HCMV in both vaccinia-immune and non-immune individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Cytomegalovirus / immunology*
  • Dose-Response Relationship, Immunologic
  • Female
  • Guinea Pigs
  • Humans
  • Mice
  • Mice, Inbred CBA
  • T-Lymphocytes, Cytotoxic / immunology
  • Vaccines, Synthetic / immunology*
  • Vaccinia virus / immunology
  • Viral Envelope Proteins / immunology*
  • Viral Vaccines / immunology*


  • Antibodies, Viral
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • Viral Vaccines
  • glycoprotein B, Simplexvirus